Wilfried Briest

Summary

Country: Germany

Publications

  1. pmc Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome
    Wilfried Briest
    Laboratory of Cardiovascular Sciences, National Institute on Aging, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 337:621-7. 2011
  2. pmc Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline, prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome
    Hyun Jin Tae
    Laboratory of Cardiovascular Science, National Institute on Aging, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 343:246-51. 2012
  3. pmc Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts
    Gerd A Müller
    Laboratory of Cardiovascular Sciences, National Institute on Aging, Baltimore, Maryland, USA
    FASEB J 26:668-77. 2012

Collaborators

  • Jing Zhang
  • Mingyi Wang
  • Mark I Talan
  • Hyun Jin Tae
  • Gerd A Müller
  • Shannon Marshall
  • Zhi Xu
  • Uwe Hansen
  • Benjamin Griswold
  • Nazli B McDonnell

Detail Information

Publications3

  1. pmc Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome
    Wilfried Briest
    Laboratory of Cardiovascular Sciences, National Institute on Aging, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 337:621-7. 2011
    ..The results suggest that doxycycline merits clinical testing as a treatment for vEDS...
  2. pmc Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline, prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome
    Hyun Jin Tae
    Laboratory of Cardiovascular Science, National Institute on Aging, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 343:246-51. 2012
    ..Our findings provide experimental justification for the clinical evaluation of the benefit of doxycycline at least in the haploinsufficient variety of vEDS...
  3. pmc Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts
    Gerd A Müller
    Laboratory of Cardiovascular Sciences, National Institute on Aging, Baltimore, Maryland, USA
    FASEB J 26:668-77. 2012
    ..Thus, the application of allele-specific RNAi may be a promising direction for future personalized therapies to reduce the severity of vEDS...